SCHEDULE 13G/A: Perceptive Advisors Reduces Stake in Iovance Biotherapeutics Below 5%

Perceptive Advisors and its affiliates have reported a decrease in their beneficial ownership of Iovance Biotherapeutics, Inc. common stock to 3.8%, falling below the 5% threshold.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their ownership in Iovance Biotherapeutics, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 12,808,788 shares of Iovance Biotherapeutics, Inc. Common Stock.
• This aggregate amount represents 3.8% of the Issuer's outstanding Common Stock.
• The ownership percentage is based on 333,934,387 shares of Common Stock outstanding as of April 30, 2025, as reported in the Issuer's Form 10-Q filed on May 8, 2025.
• The Master Fund directly holds 12,711,982 shares of Common Stock and preferred stock convertible into an additional 97,000 shares of Common Stock.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
• The filing indicates that the Reporting Persons now own 5 percent or less of the class, implying a reduction from a previous stake that was above 5%.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to a significant institutional investor reducing its stake below the 5% threshold, which can be interpreted as a loss of confidence or a strategic divestment.

Negatives

• The reduction in beneficial ownership by a significant institutional investor like Perceptive Advisors below the 5% threshold could be perceived as a negative signal by the market.

Future Outlook

N/A

Industry Context

This filing is a routine disclosure of institutional ownership changes within the biotechnology sector. A reduction in stake by a prominent life sciences investor like Perceptive Advisors could be observed by other market participants, potentially influencing sentiment towards Iovance Biotherapeutics.

Stakeholder Impact

• Shareholders: May react negatively to the news of a significant institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• Investment Professionals: Will note the change in institutional ownership as part of their analysis of Iovance Biotherapeutics.

Key Dates

Keywords

Iovance Biotherapeutics, Perceptive Advisors, Schedule 13G, Biotechnology, Institutional Ownership, SEC Filing, Common Stock, Investment Management